Free Trial
NASDAQ:FDMT

4D Molecular Therapeutics Q2 2023 Earnings Report

4D Molecular Therapeutics logo
$3.06 +0.15 (+5.15%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$2.98 -0.09 (-2.78%)
As of 04/17/2025 06:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

4D Molecular Therapeutics EPS Results

Actual EPS
-$0.77
Consensus EPS
-$0.77
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

4D Molecular Therapeutics Revenue Results

Actual Revenue
$0.24 million
Expected Revenue
$1.43 million
Beat/Miss
Missed by -$1.19 million
YoY Revenue Growth
N/A

4D Molecular Therapeutics Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Wednesday, August 9, 2023
Conference Call Time
4:00PM ET

Upcoming Earnings

4D Molecular Therapeutics' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled on Wednesday, May 14, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

4D Molecular Therapeutics Earnings Headlines

Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
4DMT Announces New Employment Inducement Grants
4DMT to Participate in Upcoming Investor Conferences
See More 4D Molecular Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 4D Molecular Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 4D Molecular Therapeutics and other key companies, straight to your email.

About 4D Molecular Therapeutics

4D Molecular Therapeutics (NASDAQ:FDMT), a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

View 4D Molecular Therapeutics Profile

More Earnings Resources from MarketBeat